Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RELIEF THERAPEUTICS Holding ( (CH:MMTX) ) has shared an announcement.
MindMaze Therapeutics has published its 2025 annual report and outlined a corporate update that underscores progress in commercializing its neurotherapeutics platform across hospital, outpatient, and home settings. The company highlighted strong real-world data from a two-year Vibra Healthcare program showing significant gains in mobility, self-care, therapy intensity, and discharge outcomes, reinforcing the scalability and clinical relevance of its digital neurorehabilitation tools.
Following the year-end business combination of NeuroX and Relief Therapeutics, MindMaze is focusing its now integrated, commercial-stage organization squarely on neurology while seeking to out-license or divest non-neurology assets. The group reported modest 2025 revenues of CHF 0.6 million against an operating loss, reflecting early-stage commercialization and investment in technology and infrastructure, and it is prioritizing U.S. scale-up, reimbursement expansion, and strategic partnerships under new CEO Zach Henderson in 2026.
To accelerate U.S. growth, MindMaze is creating a domestic headquarters and patient experience lab to serve as a hub for its sales, marketing, and customer success teams and as an engagement center for providers and partners. The company is simultaneously expanding channel partnerships with rehabilitation networks, digital health platforms, and EHR vendors while working to enhance payer coverage for home-based therapy, positioning itself to capture growing demand for technology-enabled neurological care.
More about RELIEF THERAPEUTICS Holding
MindMaze Therapeutics Holding SA is a Geneva-based neurotechnology company focused on scalable, precision neurotherapeutics for neurological disorders such as stroke and Parkinson’s disease. Its FDA-cleared and CE-marked products combine advanced software, proprietary sensors, and AI-driven analytics to deliver reimbursable therapy from hospital to home, targeting systemic shortages of specialized clinicians and aiming to redefine neurorestorative care worldwide.
Average Trading Volume: 443,899
Technical Sentiment Signal: Sell
Current Market Cap: CHF46.97M
See more insights into MMTX stock on TipRanks’ Stock Analysis page.